Sarepta Therapeutics, Inc.
As of Oct 22, 2026, Sarepta Therapeutics is in Stage 2, the uptrend phase, now in week 2 (since Oct 9, 2026). It closed at $18.18, 25.6% below its 52-week high and below its 200-day average, which is falling.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therape… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care
Is SRPT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
SRPT among Biotechnology252nd of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …252 | SRPT | Stage 2 · wk 2 | 38 | −4.1% |
Sarepta Therapeutics: quick answers
What stage is Sarepta Therapeutics in?
As of Oct 22, 2026, Sarepta Therapeutics (SRPT) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 9, 2026 and is in week 2. What the four stages mean
Is Sarepta Therapeutics in an uptrend?
Yes. Sarepta Therapeutics is in a Stage 2 uptrend. It trades 3.5% below its 200-day average, which is falling.
How far is Sarepta Therapeutics from its 52-week high?
Sarepta Therapeutics closed at $18.18 on Oct 22, 2026, 25.6% below its 52-week high of $24.45. Its 52-week low is $14.86.
How has Sarepta Therapeutics performed over the past year?
As of Oct 22, 2026, Sarepta Therapeutics is down 22.1% over the past year and down 14.7% so far in 2026.
Which sector and industry is Sarepta Therapeutics in?
Sarepta Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.